Transplantation is the transfer (engraftment) of human cells, tissues, or organs from a donor to a recipient, with the aim of restoring function(s) in the body. In case of end-state organ failure, such as liver and heart failure, organ transplantation is often the only treatment. A significant upward trend has been observed in the last two years in the transplantation therapeutics market. Factors driving the transplantation therapeutics market are rising non-communicable diseases, aging population and increasing life expectancy, growing income, rising government expenditure on health care, free trade agreement, and continuous research and development. According to Global Observatory on Donation and Transplantation, in 2015, around 126,670 solid organs, such as kidney, heart, liver, lungs, small bowel, and pancreas transplantations were performed worldwide, which is an increase of 5.8% since 2014. Kidney and the liver transplants are the widely performed transplant procedures.
Continuous research and development to provide innovative drugs and treatment for a host of diseases has boosted the development of the transplantation therapeutics. Technological innovation provided key players with the opportunity to penetrate a new therapeutic area/market. Moreover, rising number of prevalence and incidences of various diseases has increased the demand for highly innovative and better outcome products. Developing global economic conditions create lucrative opportunities for the expansion of the transplantation therapeutics market. Rise in individual per capita income boosts health care expenditure. In the developing countries of Asia Pacific and the Middle East, growing population and per capita income are important drivers of the market. According to the Economist Intelligence Unit (EIU), the number of high-income households is estimated to be around 540 million by 2019, out of which, Asia Pacific is likely to constitute a share of more than 50%. Along with growing geriatric population and life expectancy rate, other factors, such as, increase in the number of stem cell donors, decline in infant mortality, enhanced living conditions, improved sanitation, and better prevention of communicable diseases are also projected to contribute to the advancement of the market. Although there are a number of drug options available in the market for acute rejections, long-term treatment options remain unsatisfactory. Risk of infection limits the effectiveness of these therapies. As such, improvement in their efficacy is needed.
Segmentation - The global transplantation therapeutics market can be segmented based on drug class, route of administration, distribution channel, and geography. In terms of drug class, the market can be categorized into antibody therapies, calcineurin inhibitors, anti-proliferative agents, mTor inhibitors, corticosteroids, and others. Based on distribution channel, the transplantation therapeutics market can be divided into hospital pharmacies, retail pharmacies, online pharmacies, and others. The online pharmacies segment is anticipated to record a significant growth during the forecast period, owing to factors, such as, ease of access to product comparison and discounts offered online.
Region-wise, the global transplantation therapeutics market can be segmented into North America (NA), Europe, Asia Pacific (APAC), Latin America (LA), and Middle East & Africa (MEA). North America and Europe lead the global transplantation therapeutics market due to easy technological applications, funding and high income population in these regions. The other favorable reasons are high prevalence of lymphoproliferative disorders and leukemia, demand for better treatment options, and easy accessibility and acceptance of new technologies. Transplantation rate in high income countries is increasing at a rapid pace, and continued rise is also seen in low income countries and is expected to grow further. The transplantation therapeutics pipeline comprises around 120 drug candidates in different stages of development. The pipeline consists of a high number of small molecules, biologics, and other drug candidates developed as peptides and protein. Companies are targeting a wide range of therapeutics, such as chemokine receptors, integrins, cadherins, and protein kinase. However, no particular class of target appears predominating in terms of pipeline volume.
Leading players operating in the global transplantation therapeutics market are Novartis AG, GlaxoSmithKline Plc, AbbVie Inc, Pfizer Inc, Astellas Pharma Inc, Gilead Sciences Inc, Quark Pharmaceuticals Inc, Takeda Pharmaceutical Company Ltd, Sanofi, and Boehringer Ingelheim.
This study by VRR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.
Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:
The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.
The following regional segments are covered comprehensively:
The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.
Below is a snapshot of these quadrants.
1. Customer Experience Map
The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.
2. Insights and Tools
The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.
3. Actionable Results
The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.
4. Strategic Frameworks
The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.
The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:
1. What can be the best investment choices for venturing into new product and service lines?
2. What value propositions should businesses aim at while making new research and development funding?
3. Which regulations will be most helpful for stakeholders to boost their supply chain network?
4. Which regions might see the demand maturing in certain segments in near future?
5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?
6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?
7. Which government regulations might challenge the status of key regional markets?
8. How will the emerging political and economic scenario affect opportunities in key growth areas?
9. What are some of the value-grab opportunities in various segments?
10. What will be the barrier to entry for new players in the market?
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers